Document is current
Any future updates will be listed below
-
Authors
Clack, Glen https://orcid.org/0000-0002-7782-9891
Moore, Christopher https://orcid.org/0000-0002-3213-9600
Ruston, Linette https://orcid.org/0009-0003-0939-1650
Wilson, David
Koch, Annelize
Webb, Danielle
Mallard, Nicholas https://orcid.org/0009-0009-1983-6637
-
Clinical Trials BETA
Clinical trials referenced in this document:
isrctn9628565 at ISRCTN.orgDocuments that mention this clinical trial
A Phase 1 Randomized, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enteric-Coated Stabilized Sulforaphane (SFX-01) in Male Participants
https://doi.org/10.1007/s12325-024-03018-1
-
Funding
Funding for this research was provided by:
TheraCryf PLC
- License Information
-
More Information
Article History
Received: 22 July 2024
Accepted: 2 October 2024
First Online: 9 November 2024
Declarations
:
: Glen Clack is an employee of TheraCryf PLC; Glen Clack is also the managing director of Alise Onclogy Ltd which is a shareholder of TheraCryf PLC. Nicholas Mallard is an employee of TheraCryf PLC. Annelize Koch and Danielle Webb are employees of Simbec-Orion. Christopher Moore is an employee of Boyds (working for TheraCryf PLC). Linette Ruston is an employee of Seda Pharmaceutical Development Services (working for ThereCryf PLC). David Wilson is an employee of DJWstats consulting (working for TheraCryf PLC).
: All participants provided written informed consent to participate in the study. Participants were free to withdraw from the study at any time. The study protocol, together with participant information and consent forms, were reviewed and approved by Wales Research Ethics Committee 1. This study was conducted in accordance with the Declaration of Helsinki and complies with the International Council for Harmonisation Good Clinical Practice guidelines and applicable UK regulatory requirements.
